Clomiphene citrate down-regulates estrogen receptor-α through the ubiquitin-proteasome pathway in a human endometrial cancer cell line

Molecular and Cellular Endocrinology

Volumn 428, Issue , 2016, Pages 142-147

  Amita, Mitsuyoshi ^a   Takahashi, Toshifumi ^a   Igarashi, Hideki ^a   Nagase, Satoru ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Clomiphene citrate; Endometrium; Estrogen receptor ; Proteasome; Ubiquitination

Indexed keywords

CLOMIFENE CITRATE; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PROTEASOME; UBIQUITIN; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CLOMIFENE; ESTROGEN RECEPTOR ALPHA, HUMAN; GREEN FLUORESCENT PROTEIN; LEUPEPTIN; LIGAND;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOMETRIAL CANCER CELL LINE; ERALPHA GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; PREGNANCY RATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; UBIQUITINATION; WESTERN BLOTTING; DRUG EFFECTS; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CLOMIPHENE; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; LEUPEPTINS; LIGANDS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; PROTEOLYSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 84962157125     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.03.029     Document Type: Article

References (48)

1. Aksel S., Saracoglu O.F., Yeoman R.R., Wiebe R.H. Effects of clomiphene citrate on cytosolic estradiol and progesterone receptor concentrations in secretory endometrium. Am. J. Obstet. Gynecol. 1986, 155:1219-1223.
2. Amita M., Takahashi T., Tsutsumi S., Ohta T., Takata K., Henmi N., Hara S., Igarashi H., Takahashi K., Kurachi H. Molecular mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation by clomiphene citrate. Endocrinology 2010, 151:394-405.
3. Ben-Nissan G., Sharon M. Regulating the 20S proteasome ubiquitin-independent degradation pathway. Biomolecules 2014, 4:862-884.
4. Berry N.B., Fan M., Nephew K.P. Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol. Endocrinol. 2008, 22:1535-1551.
5. Bouchard P., Marraoui J., Massai M.R., Medalie D.A., De Ziegler D., Perrot-Applanat M., Frydman R., Bergeron C. Immunocytochemical localization of oestradiol and progesterone receptors in human endometrium: a tool to assess endometrial maturation. Baillieres Clin. Obstet. Gynaecol. 1991, 5:107-115.
6. Bromer J.G., Aldad T.S., Taylor H.S. Defining the proliferative phase endometrial defect. Fertil. Steril. 2009, 91:698-704.
7. Chakraborty P.K., Brown J.L., Ruff C.B., Nelson M.F., Mitchell A.S. Effects of long-term treatment with estradiol or clomiphene citrate on bone maintenance, and pituitary and uterine weights in ovariectomized rats. J. Steroid Biochem. Mol. Biol. 1991, 40:725-729.
8. Crewe H.K., Ghobadi C., Gregory A., Rostami-Hodjegan A., Lennard M.S. Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 847:296-299.
9. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106(Pt 4):1377-1388.
10. Devin-Leclerc J., Meng X., Delahaye F., Leclerc P., Baulieu E.E., Catelli M.G. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol. Endocrinol. 1998, 12:842-854.
11. Eakin C.M., Maccoss M.J., Finney G.L., Klevit R.E. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A 2007, 104:5794-5799.
12. Eden J.A., Place J., Carter G.D., Jones J., Alaghband-Zadeh J., Pawson M.E. The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet. Gynecol. 1989, 73:187-190.
13. El Khissiin A., Leclercq G. Implication of proteasome in estrogen receptor degradation. FEBS Lett. 1999, 448:160-166.
14. Friedler S., Schenker J.G., Herman A., Lewin A. The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review. Hum. Reprod. Update 1996, 2:323-335.
15. Fritz M.A., Holmes R.T., Keenan E.J. Effect of clomiphene citrate treatment on endometrial estrogen and progesterone receptor induction in women. Am. J. Obstet. Gynecol. 1991, 165:177-185.
16. Glasier A.F. Clomiphene citrate. Baillieres Clin. Obstet. Gynaecol. 1990, 4:491-501.
17. Gonen Y., Casper R.F. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum. Reprod. 1990, 5:670-674.
18. Gonen Y., Calderon I., Dirnfeld M., Abramovici H. The impact of sonographic assessment of the endometrium and meticulous hormonal monitoring during natural cycles in patients with failed donor artificial insemination. Ultrasound Obstet. Gynecol. 1991, 1:122-126.
19. Hecht B.R., Khan-Dawood F.S., Dawood M.Y. Peri-implantation phase endometrial estrogen and progesterone receptors: effect of ovulation induction with clomiphene citrate. Am. J. Obstet. Gynecol. 1989, 161:1688-1693.
20. Htun H., Holth L.T., Walker D., Davie J.R., Hager G.L. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol. Biol. Cell. 1999, 10:471-486.
21. Jimenez M.A., Magee D.E., Bryant H.U., Turner R.T. Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 1997, 138:1794-1800.
22. Kadiyala V., Smith C.L. Minireview: the versatile roles of lysine deacetylases in steroid receptor signaling. Mol. Endocrinol. 2014, 28:607-621.
23. Kokko E., Janne O., Kauppila A., Vihko R. Cyclic clomiphene citrate treatment lowers cytosol estrogen and progestin receptor concentrations in the endometrium of postmenopausal women on estrogen replacement therapy. J. Clin. Endocrinol. Metab. 1981, 52:345-349.
24. Kousta E., White D.M., Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update 1997, 3:359-365.
25. Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid Biochem. Mol. Biol. 2005, 94:347-359.
26. Lonard D.M., Nawaz Z., Smith C.L., O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell. 2000, 5:939-948.
27. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 2006, 281:9607-9615.
28. Marsaud V., Gougelet A., Maillard S., Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 2003, 17:2013-2027.
29. McDonnell D.P. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin. Cancer Res. 2005, 11:871s-877s.
30. Merin N.M., Kelly K.R. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharm. (Basel) 2014, 8:1-20.
31. Nakamura Y., Ono M., Yoshida Y., Sugino N., Ueda K., Kato H. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil. Steril. 1997, 67:256-260.
32. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U. S. A 1999, 96:1858-1862.
33. Nonclercq D., Journe F., Body J.J., Leclercq G., Laurent G. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Mol. Cell Endocrinol. 2004, 227:53-65.
34. Parker M.G. Structure and function of estrogen receptors. Vitam. Horm. 1995, 51:267-287.
35. Peeraer K., Debrock S., De Loecker P., Tomassetti C., Laenen A., Welkenhuysen M., Meeuwis L., Pelckmans S., Mol B.W., Spiessens C., De Neubourg D., D'Hooghe T.M. Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial. Hum. Reprod. 2015, 30:1079-1088.
36. Pellom S.T., Shanker A. Development of proteasome inhibitors as therapeutic drugs. J. Clin. Cell Immunol. 2012, S5:5.
37. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 1997, 18:306-360.
38. Randall J.M., Templeton A. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil. Steril. 1991, 56:465-468.
39. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell. 2003, 11:695-707.
40. Robyr D., Wolffe A.P., Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol. 2000, 14:329-347.
41. Senturk L.M., Erel C.T. Thin endometrium in assisted reproductive technology. Curr. Opin. Obstet. Gynecol. 2008, 20:221-228.
42. Stenoien D.L., Mancini M.G., Patel K., Allegretto E.A., Smith C.L., Mancini M.A. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. Mol. Endocrinol. 2000, 14:518-534.
43. Stenoien D.L., Patel K., Mancini M.G., Dutertre M., Smith C.L., O'Malley B.W., Mancini M.A. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nat. Cell Biol. 2001, 3:15-23.
44. Turner R.T., Evans G.L., Sluka J.P., Adrian M.D., Bryant H.U., Turner C.H., Sato M. Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene. Endocrinology 1998, 139:3712-3720.
45. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276:35684-35692.
46. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 1996, 3:87-94.
47. Xia Y., Zhou F., Huang H. Effects of clomiphene citrate treatment on endometrial estrogen and progesterone receptors expressions. Zhonghua Fu Chan Ke Za Zhi 1996, 31:606-609.
48. Yeh W.L., Shioda K., Coser K.R., Rivizzigno D., McSweeney K.R., Shioda T. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor alpha protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS One 2013, 8:e60889.